Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: TBPH

Theravance Biopharma, Inc.

Healthcare | Biotechnology

No licensed closing price on file for TBPH. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$1.01

Theravance Biopharma, Inc. (NASDAQ: TBPH) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-19 23:24 UTC.

What Theravance Biopharma, Inc. does

Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing medicines. The company's primary commercial product is YUPELRI, an FDA-approved inhalation solution for maintenance treatment of chronic obstructive pulmonary disease, which is co-commercialized with partner Viatris Inc. in the United States under a profit and loss sharing arrangement. In 2025, YUPELRI achieved net sales growth, and the company received a milestone payment for reaching $250 million in US net sales.

Summarized from Theravance Biopharma, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

TBPH no longer appears among SEC's registered filers -- it may have been acquired, merged, or delisted. The figures on this page reflect the company's final filings and are no longer refreshed.

Key facts

Valuation
EPS (TTM)$1.01
Return on equity35.69%

Revenue, margins & earnings

FY2021: net loss $199M on revenue $55M$55MFY2021FY2022 Revenue: $51M — margin split not shown (non-operating gains)FY2022: net income $872M exceeded revenue $51M by $821M — non-operating gains (e.g. asset sales), not operating profit$51MFY2022FY2023: net loss $55M on revenue $57M$57MFY2023FY2024: net loss $56M on revenue $64M$64MFY2024FY2025 Revenue: $107M — margin split not shown (non-operating gains)$107MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net income above revenue (non-operating gains)
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
Gold cap: net income exceeded revenue that year from non-operating gains (e.g. asset sales), not operating profit.

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-28
  • 2026-09-28InsiderOther-7,457,060$126.77M
  • 2026-09-24DirectorShare Option (Right to Buy)Returned to company-28,000—
  • 2026-09-24DirectorShare Option (Right to Buy)Returned to company-17,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Theravance Biopharma, Inc. do?

Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing medicines.

When did TBPH last file with the SEC?

Theravance Biopharma, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-29. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-19 23:24 UTC. This page is also available as JSON at /api/data?ticker=TBPH and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for TBPH and 5,000+ tickers.

Create a free account — keep TBPH
For your agent
GET /api/data?ticker=TBPH

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt